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ABSTRACT
Obesity is a significant risk factor for ovarian cancer (OC) and associated 
with worse outcomes for this disease. We assessed the anti-tumorigenic effects of 
metformin in human OC cell lines and a genetically engineered mouse model of high 
grade serous OC under obese and lean conditions. Metformin potently inhibited growth 
in a dose-dependent manner in all four human OC cell lines through AMPK/mTOR 
pathways. Treatment with metformin resulted in G1 arrest, induction of apoptosis, 
reduction of invasion and decreased hTERT expression. In the K18-gT121+/-; p53fl/ fl; 
Brca1fl/fl (KpB) mouse model, metformin inhibited tumor growth in both lean and 
obese mice. However, in the obese mice, metformin decreased tumor growth by 
60%, whereas tumor growth was only decreased by 32% in the lean mice (p=0.003) 
compared to vehicle-treated mice. The ovarian tumors from obese mice had evidence 
of impaired mitochondrial complex 2 function and energy supplied by omega fatty acid 
oxidation rather than glycolysis as compared to lean mice, as assessed by metabolomic 
profiling. The improved efficacy of metformin in obesity corresponded with inhibition 
of mitochondrial complex 1 and fatty acid oxidation, and stimulation of glycolysis in 
only the OCs of obese versus lean mice. In conclusion, metformin had anti-tumorigenic 
effects in OC cell lines and the KpB OC pre-clinical mouse model, with increased 
efficacy in obese versus lean mice. Detected metabolic changes may underlie why 
ovarian tumors in obese mice have heightened susceptibility to metformin.
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INTRODUCTION
Epithelial ovarian cancer (OC) is the leading cause 
of death from gynecological malignancies and the fifth 
leading cause of cancer-related death among women in the 
United States [1]. Due to the asymptomatic nature of early 
stage disease, women are diagnosed with advanced stage 
disease in more than 70% of cases, with an overall 5-year 
survival of only 30-40% [2, 3]. Obesity is an important 
risk factor for OC and is associated with worse outcomes 
for this disease [4–18], with up to a 1.5 fold increased risk 
of death [10]. Therefore, a targeted metabolic approach 
to the treatment of OC may provide a novel strategy to 
improve outcomes for this invariably lethal disease.
Excess fuel storage in obesity culminates in 
stimulated growth factor signaling via the insulin/insulin-
like growth factor (IGF-1) axis, and can lead to a nutrient-
saturated environment with high levels of glucose and 
other nutrients [19]. Hyperinsulinemia, IGF-1 and IGF-1 
receptor (IGF-1R) levels are known to be important in OC 
development and progression [20–23] through interactions 
with the downstream PI3K/Akt/mTOR pathway [24–
27]. Components of this pathway are often mutated, 
amplified, or aberrantly expressed in OCs, and are 
currently being targeted for OC treatment [28–34]. Given 
the interplay between obesity, insulin/glucose signaling 
and OC, we hypothesized that obesity creates a unique 
environment contributing to the generation of tumors 
that are metabolically distinct from those developing in a 
“lean” host milieu. In support of this hypothesis, we have 
previously reported that diet-induced obesity (DIO) in 
the K18-gT121
+/-; p53fl/fl; Brca1fl/fl (KpB) OC mouse model 
results in a tripling of tumor growth [35]. Furthermore, 
significant genomic and metabolic differences were 
demonstrated between ovarian tumors that arose in obese 
versus lean mice [35]. Thus, obesity-driven tumors may 
have metabolic vulnerabilities that could be targetable for 
treatment with agents such as metformin.
Metformin is an effective, well-tolerated and 
inexpensive medication for improving hyperglycemia in 
the treatment of type 2 diabetes [36]. Epidemiological 
evidence suggests that metformin lowers cancer risk 
and reduces cancer incidence and deaths among diabetic 
patients [37–40], including OC [41–44]. This has led to 
the hypothesis that metformin could be used for cancer 
treatment and prevention.
Metformin may have both indirect and direct effects 
on tumor growth [45]. Its indirect effects are postulated 
to be due to a reduction in circulating glucose and insulin 
levels in the host via inhibition of gluconeogenesis in the 
liver, and subsequent decreased growth factor stimulation 
in tumor cells. On the cellular or direct level, metformin 
inhibits mitochondrial respiratory complex I, leading 
to suppression of tricarboxylic acid (TCA) cycle flux, 
interrupted oxidative phosphorylation, and decreased 
mitochondrial ATP production [45–48]. The resulting 
cellular energetic stress from inhibition of complex I raises 
the AMP/ATP ratio, resulting in increased AMPK signaling 
and stimulated glycolysis and fatty acid oxidation. AMPK 
is a central regulator of multiple signaling pathways that 
control cellular proliferation and metabolism, including 
inhibition of the mTOR pathway (i.e. specifically 
mTORC1) [45]. In addition, metformin inhibits the 
mTOR pathway via AMPK-independent mechanisms, 
potentially through its effects on the Ragulator complex 
(Rag GTPase) and REDD1 upregulation or via enhanced 
PRAS40 binding to RAPTOR [45, 49–52]. Thus, a drug 
such as metformin that decreases circulating glucose 
and insulin levels, inhibits mitochondrial complex I, and 
disrupts the mTOR pathway may be useful in obesity- and 
mTOR pathway-driven cancers, such as OC. Given this, 
our goal was to evaluate the anti-tumorigenic effects of 
metformin in human OC cell lines and the KpB genetically 
engineered mouse model of high grade serous OC under 
both lean and obese conditions.
RESULTS
Metformin inhibited cell proliferation in 
OC cells
In all four OC cell lines, treatment with metformin 
resulted in the inhibition of cell proliferation in a dose-
dependent manner compared to vehicle-treated controls. 
The mean IC50 for the OC cell lines after 72 h of treatment 
was between 0.1 and 13 mM (Figure 1A). Of all the OC 
cell lines tested, the IGROV1 cells were found to be the 
most sensitive to metformin.
The primary cellular target of metformin is 
mitochondrial respiratory-chain complex 1. To determine 
if metformin treatment inhibited complex 1 activity 
in the OC cell lines, cells were treated with increasing 
concentrations of metformin for 24 h and then the activity 
of complex 1 was measured by ELISA assay. Metformin 
significantly inhibited cellular complex 1 activity in a 
dose-dependent manner (p<0.5) (Figure 1B).
Given that hTERT expression is thought to be a 
sensitive marker of telomerase function as well as cell 
proliferation [53], we evaluated hTERT mRNA and 
protein expression in all four OC cell lines. Real-time 
RT-PCR was used to quantify hTERT mRNA expression, 
and Western immunoblotting was used to quantity hTERT 
protein expression in all four OC cell lines. Treatment with 
metformin for 24 h significantly decreased the expression 
of hTERT mRNA (p<0.05-0.01) and protein in a dose-
dependent manner in all of the OC cell lines (Figure 1C 
and 1D), suggesting that metformin may inhibit telomerase 
activity through rapidly decreasing hTERT expression.
Effect of metformin on cell cycle progression and 
apoptosis
To evaluate the mechanism of growth inhibition 
by metformin, its effects on cell cycle progression 
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and induction of apoptosis were analyzed after 36 h of 
treatment. As expected, metformin significantly induced 
G1 cell cycle arrest and reduced the number of cells in 
S phase in a dose-dependent manner in all four OC cells 
(p<0.05-0.01) (Figure 2A). To confirm whether the growth 
inhibition of ovarian cells in vitro was related in part to 
apoptosis, we evaluated the apoptotic effect of metformin 
on the OC cell lines by Annexin-V FITC stain analysis. 
This assay detects the phospholipid phosphatidylserine 
(PS) translocated from the inner (cytoplasmic) leaflet of 
the cell membrane to the external surface in very early 
apoptotic cells. As shown in Figure 2B, the percentage of 
apoptotic cells increased in a dose-dependent manner in 
the OC cell lines after 24 h of treatment with metformin 
(p<0.05).
In addition, we examined the effect of metformin on 
the activity of the caspase family of proteins to determine 
whether caspase activation contributes to metformin-
induced OC cell apoptosis. Caspase 3, a specific marker 
for epithelial apoptosis, was assessed by ELISA assay. 
Metformin increased caspase 3 activity in the OC cell lines 
at doses of 1 and 10 mM (p<0.05) (Figure 2C).
Effect of metformin on the AMPK and mTOR 
pathway
To investigate the mechanisms underlying the 
inhibition of cell proliferation by metformin, we 
characterized the effect of metformin on relevant 
downstream signaling targets and pathways. Metformin 
induced phosphorylation of AMPK in a dose-dependent 
manner in all the OC cell lines, within 18 h of exposure 
(Figure 3A-3D). To further evaluate whether metformin 
affects the mTOR pathway via AMPK in the OC cells, we 
examined the phosphorylation of ribosomal protein S6, a 
downstream target of AMPK/mTOR. Metformin inhibited 
phosphorylation of S6 in a dose-dependent manner after 
18 h of treatment in the OC cell lines, with the exception 
of the CAOV3 cells, for which metformin only inhibited 
phosphorylation of S6 at high doses (>5 mM, Figure 3B). 
Expression of pan-AMPK and pan-S6 was not affected 
by metformin. These findings suggest that metformin may 
exert its anti-tumor activity via activation of AMPK and 
subsequent inhibition of the mTOR pathway, resulting in 
decreased phosphorylation of S6.
Figure 1: Effect of metformin on proliferation of human OC cells. The CAOV3, IGROV1, OVCAR3 and SKOV3 cells were 
cultured in the presence of varying concentrations of metformin (0.001 – 25 mM) for 72 h. Cell proliferation was determined by MTT assay. 
Metformin significantly inhibited cell proliferation in all four cell lines (A). Metformin significantly reduced cellular complex 1 activity in 
a dose-dependent manner after 24 h of treatment (B). Metformin decreased hTERT mRNA expression and hTERT protein expression in a 
dose dependent manner (C and D). The results are shown as the mean ± SE of triplicate samples and are representative of three independent 
experiments. *p<0.05, **p<0.01.
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Figure 2: Metformin induced cell cycle G1 arrest and apoptosis. The OC cell lines, SKOV3, CAOV3, OVCAR3 and IGROV1, 
were treated with metformin at the indicated concentrations for 36 h. Cell cycle analysis was performed by flow cytometry, and metformin 
was found to induce G1 arrest at dose of 1-25 mM (A). Metformin increased Annexin V expression after 24 h of treatment (B), and induced 
cleaved caspase 3 activity after 12 h treatment (C) in the OC cell lines. Results shown are representative of two independent experiments. 
*p<0.05, **p<0.01.
Figure 3: Metformin increased phosphorylation of AMPK and decreased phosphorylation of S6 in the OC cell lines. 
The four OC cell lines were treated with metformin for 16 h. Protein was subsequently extracted, and western immunoblotting performed. 
Metformin induced expression of phosphorylated-AMPK and decreased expression of the phosphorylated-S6 protein. Results shown are 
one of three independent experiments.
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Effect of metformin on OC cell adhesion and 
invasion
Adhesion and invasion are believed to be important 
steps in OC metastasis. To evaluate the role of metformin 
on adhesion and invasion of OC cells, an in vitro adhesion 
assay and ChemoTx® invasion assay were employed. 
Cell adhesion was decreased by 24-37% in all four OC 
cell lines after treatment with metformin versus vehicle 
at a dose of 10 mM for 2 h (p<0.05-0.01) (Figure 4A). 
In addition, metformin decreased cell invasion in all four 
cell lines after 4 h of treatment. At a dose of 10 mM, 
metformin reduced invasion by 30-42% compared to 
vehicle-treated groups (p<0.05-0.01) (Figure 4B). The 
inhibition of adhesion and invasion by metformin was 
dose-dependent for all cell lines tested. These results 
suggest that metformin may blunt OC cell adhesion and 
invasion, in addition to inducing cell cycle arrest and 
apoptosis.
Effect of metformin on tumor growth in obese 
and lean KpB mice
During the 4 weeks of metformin or vehicle 
treatment, the obese and lean KpB mice demonstrated 
tolerance of metformin and maintained normal activities. 
Regular twice-weekly measurements yielded no changes 
in blood glucose or body weight (data not shown) during 
treatment. At the time of sacrifice, the HFD-fed mice 
(obese) weighed a mean of 49.13 grams (gm) versus 
only 30.24 gm in the LFD-fed mice (lean) (p<0.01, data 
not shown). Tumor size was assessed by both tumor 
volume and tumor weight. Obesity significantly promoted 
tumor growth compared to lean mice group. Metformin 
inhibited tumor volume growth and weight in both the 
obese and lean mice after 4 weeks of treatment (Figure 
5A and 5B). However, metformin-mediated decreases in 
tumor volume/weight in obese mice were significantly 
greater than in lean mice (60% versus 32%, respectively, 
p=0.003), suggesting that metformin’s anti-tumorigenic 
efficacy may be augmented in the obese state. ELISA 
assay showed that the production of VEGF in serum was 
significantly reduced following metformin treatment in 
both obese and lean KpB mice compared to the controls 
(p<0.01-0.05) (Figure 5C).
Immunohistochemical analysis was performed 
on the ovarian tumors after treatment with metformin 
or vehicle to assess effects on proliferation, apoptosis, 
and downstream targets of the mTOR pathway (Figure 
5D). As compared to vehicle-treated mice, metformin 
decreased Ki-67, a marker of cell proliferation, and 
increased caspase-3, a marker of apoptosis, in the ovarian 
tumors of obese and lean KpB mice (p<0.05-0.01). In 
addition, metformin increased phosphorylation of AMPK 
(i.e. activating it) and decreased phosphorylation of S6, a 
downstream target of the mTOR pathway (p<0.05-0.01). 
Treatment with metformin also resulted in decreased 
expression of matrix metalloproteinase 9, a protein 
involved in the degradation of the extracellular matrix 
and subsequent invasion, in both the obese and lean KpB 
mice. Together, these in vivo findings in the KpB mouse 
model of OC support the in vitro findings in OC cell 
lines, suggesting that treatment with metformin decreases 
cell proliferation, induces apoptosis, reduces adhesion/
invasion, activates AMPK and inhibits the mTOR 
pathway.
Metabolic effects of metformin in the ovarian 
tumors of obese and lean mice
Metabolomic profiling revealed metabolic 
differences between the ovarian tumors from obese and 
lean KpB mice. 58 up- or down-regulated metabolites 
differentiated ovarian tumors in obese (obese-OCs) versus 
lean mice (lean-OCs) (Table 1 and Figure 6). Random 
Forest (RF) analysis distinguished an ovarian tumor as 
lean or obese with a predictive accuracy of 100%. Most 
strikingly, glucose levels were 3-fold higher in the ovarian 
tumors of the obese versus lean mice (p<0.05), and were 
accompanied by decreases in downstream intermediates 
Figure 4: Metformin inhibited cell adhesion and invasion. The four OC cell lines were treated with metformin at the indicated 
doses for 2 to 4 h. Adhesion was assessed by laminin-1 assay (A), and invasion was detected by ChemoTx® invasion assay (B). Metformin 
inhibited adhesion and invasion in all four cell lines. The results are shown as the mean ± SD and are representative of three independent 
experiments. *p<0.05, **p<0.01.
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of glycolysis, including pyruvate and lactate, indicating 
impaired glycolysis. Glutamine (1.7 fold) were also 
increased in the tumors from obese mice. Omega fatty 
oxidation appeared to be stimulated in the setting of 
obesity, as evidenced by decreases in n3 and n3 fatty 
acids (1.2 – 1.6 fold) and a 3-4 fold increase in several 
acyl-carnitines and dicarboxylic acids. Lysolipids were 
also significantly decreased in the ovarian tumors from 
obese versus lean mice (1.2 – 1.7 fold). Lastly, succinate 
levels were almost 5-fold higher in the ovarian tumors 
from obese versus lean mice, with a parallel decrease 
in fumarate and malate, indicating impaired succinate 
dehydrogenase (complex II) activity.
Metabolic differences were also noted in the ovarian 
tumors from lean and obese KpB mice after metformin 
treatment (Table 2). Glucose levels were initially high 
within ovarian tumors of obese mice, falling with 
metformin treatment. Glycolysis was increased in the 
ovarian tumors of obese mice treated with metformin as 
compared to lean mice, as evidenced by elevations in 
glucose-6-phosphate (1.82 fold), fructose-6-phosphate 
(2.3 fold), fructose-1,6-bisphosphate (2.4 fold), 
2,3-diphosphoglycerate (13.9 fold), dihydroxyacetone 
phosphate (2.44 fold) and most importantly, lactate (1.36 
fold). Succinate levels decreased (1.8) while fumarate (1.6 
fold) and malate (1.3 fold) increased in metformin-treated 
tumors from obese as compared to lean mice, suggesting 
a block in the conversion of malate to oxaloacetate 
(complex I activity). In addition, n3 and n6 fatty acids 
were increased with metformin treatment in obese- versus 
lean OCs (1.12 – 3.75 fold), indicating an inability to 
oxidize fatty acids when mitochondrial complex I and II 
are inhibited. In only the OCs of obese mice, metformin 
treatment resulted in elevations in lysolipids (2.2 – 4.7 
fold). Glutamate also appeared to be oxidized in obese- 
as compared to lean-OCs, resulting in increases in 
α-ketoglutarate (1.53 fold), glucosamine-6-phosphate (1.8 
fold) and N-acetylglucosamine-6-phosphate (2.13 fold).
DISCUSSION
In this study, we investigated the potential anti-
tumorigenic activity of metformin in four human OC cell 
lines and a genetically engineered mouse model of serous 
Figure 5: Metformin inhibited ovarian tumor growth in obese and lean KpB mice. The KpB mice were fed a HFD (obese) 
or LFD (non-obese) starting at 3 weeks of age. Once a 1 cm ovarian tumor was palpated, mice underwent treatment with metformin (20 
mg/kg oral gavage) versus vehicle for 4 weeks. Metformin significantly inhibited tumor volume and tumor weight (A and B). Metformin 
reduced the level of serum VEGF in the HFD- and LFD-fed mice groups (C). The effect of metformin on expression of Ki-67, phos-AMPK, 
phos-S6, cleaved caspase 3 and MMP-9 was assessed by immunohistochemistry (D). *p<0.05, p**<0.01.
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Table 1: Comparison of metabolic differences between the ovarian tumors from obese and lean KpB mice






Isobar: F1, 6BP, G1, 6BP, myo-INS BPs 0.45
Pyruvate 0.48
Lactate 0.76
TCA cycle Succinate 4.84
Fumarate 0.62
Malate 0.71





n3 and n6 Eicosapentaenoate 0.52

























*dark green and red = p<0.05, light green and pink = p<0.1.
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OC under obese and lean conditions. In the OC cell lines, 
metformin was found to inhibit cellular proliferation via 
G1 phase cell cycle arrest, induce apoptosis, suppress 
hTERT mRNA expression and block cellular adhesion 
and invasion. Treatment with metformin resulted in the 
rapid activation of AMPK and decreased phosphorylation 
of ribosomal S6 kinase (S6K) in a dose-dependent manner, 
consistent with metformin’s known effect on mTOR 
pathway inhibition. In addition, we found that metformin 
had profound anti-tumorigenic effects in the KpB OC 
model; importantly, metformin was more efficacious 
in the tumors of obese (“obese-OC”) versus lean mice 
(“lean-OC”) that aligned with distinct metabolic effects 
depending on obesity status. Thus, our in vitro and in 
vivo studies support a potential role for metformin in OC, 
especially for obesity-drive disease.
Controlling energy metabolism is a fundamental 
requirement for cancer cells. AMPK is believed to be a 
key player in the regulation of energy metabolism [49, 
54]. LKB1 and Ca++/calmodulin-dependent protein 
kinase kinase-B (CaMKKB) have been identified as two 
upstream kinases involved in regulating the activity of 
AMPK [55]. Activation of AMPK by metformin results 
in the regulation of multiple downstream signaling 
pathways involved in the control of protein, fatty acid 
and lipid synthesis, ultimately resulting in cancer cell 
growth inhibition through cell cycle arrest and apoptosis. 
AMPK’s immediate downstream targets include mTOR, 
which regulates S6 and 4EBP1, fatty-acid synthase (FAS), 
and p53/p21 [54]. Up-regulation of the PI3K/Akt/mTOR 
pathway has been documented in many cancers [56], 
including OC [28–34], and inhibition of this pathway is 
thought to be a promising therapeutic target for cancer 
treatment. Notably, numerous studies have shown that 
metformin significantly inhibits cancer cell proliferation 
and tumor growth in mouse models for many different 
cancers, including breast, colon, pancreatic, prostate, 
endometrial, and lung cancer, among others [36, 46, 
57]. Our results confirm that metformin suppresses 
proliferation of OC cells in a dose–dependent manner in 
vitro (Figure 1) and inhibits tumor growth in vivo in the 
KpB mouse model, suggesting that the anti-tumor activity 
of metformin may have a therapeutic application in a 
broad spectrum of cancers, including OC.
Telomerase is composed of an RNA template 
(hTR) and the catalytic reverse transcriptase (hTERT), 
with hTERT acting as the rate-limiting determinant in 
the formation of functional telomerase [58]. In most 
normal, somatic cell types including normal ovarian 
tissues, telomerase activity is usually undetectable [59]. 
However, more than 90-97% of OCs express telomerase 
activity and hTERT mRNA expression [59]. Activation 
of telomerase and increased hTERT mRNA expression 
are thought to be markers of cell proliferation as well as 
represent a fundamental step in carcinogenesis in many 
cancers [58]. Since cancer and aging may share certain 
molecular processes, it is plausible that metformin may 
prevent and treat cancer by acting on the aging process 
including inhibition of telomerase activity [60, 61]. Our 
findings demonstrate for the first time that metformin 
inhibits hTERT mRNA in a dose-dependent manner in 
OC cells, indicating that hTERT may be another target for 
metformin in the inhibition of OC growth and potentially 
a sensitive biomarker for accessing the cellular response 
to metformin in vivo and in vitro. It is possible that this 
effect of metformin on hTERT is mediated through the 
mTOR pathway, as inhibition of AKT/mTOR has been 
shown to suppress telomerase activity and hTERT mRNA 
expression in a number of cancers [62, 63].
In OC, metastasis is believed to occur through cells 
detaching from the primary tumor and subsequently re-
adhering to the intra-peritoneal cavity and invading across 
the basal lamina into the stroma. Invasion and metastasis 
are the leading causes for recurrence, poor prognosis and 
death in OC [64]. Adhesion and invasion are early steps 
involved in the metastatic process for OC, which has a 
complex molecular basis that likely involves adhesion 
molecules, cell surface receptors, oncogenes, chloride 
channels, fatty acid synthase and focal adhesion kinase 
[65–69]. Several studies have reported that metformin 
inhibits adhesion and invasion in vitro in a variety of 
different cancers through multiple cell singling pathways, 
such as NF-kB, MMP-2/9, AKT/ERK1/2, PKC and 
JUK/AP-1 [70–73]. Further supporting a link between 
metformin and metastatic potential, we found that 
metformin significantly inhibited adhesion and invasion 
in all four OC cells tested and led to a decrease in matrix 
metalloproteinase-9 (MMP-9) in ovarian tumors in the 
KpB mice, an enzyme intricately linked to extracellular 
matrix remodeling and angiogenesis.
Given that energy regulation is important in 
tumorigenesis and is altered by obesity, we evaluated the 
effects of metformin after first inducing obesity through 
dietary changes (HFD versus LFD) in the KpB mouse 
model. As seen in previous studies of metformin in OC 
mouse models [73–75], metformin inhibited tumor growth 
in the KpB mouse model. However, while metformin 
inhibited tumor growth in both the HFD- and LFD-fed 
mice, metformin had a more potent effect in the HFD-
fed mice (60% decrease in HFD-fed mice, 32% decrease 
in LFD-fed mice). These results suggest that metformin 
may be a more beneficial therapeutic strategy in an 
obese versus lean host. Immunohistochemical analysis 
revealed that metformin decreased cell proliferation, 
induced apoptosis, and activated AMPK with subsequent 
downstream inhibition of S6 protein in the ovarian tumors 
of obese and lean mice, which is consistent with prior 
data [73] and our in vitro findings. Serum VEGF levels 
also decreased with metformin treatment in both obese 
and lean KpB mice, consistent with metformin’s known 
impact on angiogenic pathways. Overall, our findings are 
consistent with those demonstrated in a syngeneic OC 
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model, whereas metformin and calorie restriction were 
both found to have greater impact on inhibition of tumor 
growth in HFD- versus LFD-fed mice [75]. Animal studies 
in other cancers have also evaluated the relationship 
between obesity and efficacy of metformin and found 
similar results to ours [76–78]. In particular, in both lung 
and breast cancer animal models, metformin was found to 
be more effective in decreasing tumor growth in animals 
fed a HFD compared to a low fat or standard diet [79, 80]. 
Furthermore, in a randomized, placebo-controlled pre-
operative window study in breast cancer patients, women 
with higher body mass index (BMI) and Homeostatic 
Model Assessment of Insulin Resistance (HOMA) indexes 
had a greater response to metformin as evidenced by a 
decrease in Ki-67 staining [81]. These findings suggest 
that the anti-tumorigenic effects of metformin may be 
heightened in the setting of obesity and insulin resistance, 
due to its ability to improve the metabolic milieu of 
patients either indirectly or directly.
However, in striking contrast, metformin treatment 
has been found to elicit greater reductions in tumor growth 
in normoglycemic versus hyperglycemic conditions 
in a syngeneic OC mouse model [82], suggesting that 
metformin may have greater anti-tumorigenic efficacy 
in non-diabetic as opposed to diabetic patients. Taken 
together, these findings and ours emphasize that 
hyperglycemia and obesity are not interchangeable in 
their impact on modifying metformin response for cancer 
treatment. Further studies are needed to tease out the 
impact of high fat diet-induced versus hyperglycemia on 
metformin response in OC.
Metabolomic profiling profoundly delineated the 
effects of obesity on OC pathogenesis as well as suggested 
potential underlying mechanisms to metformin’s 
heightened efficacy in the setting of obesity (Figure 6). 
Metabolomic profiling revealed that glycolysis was 
preferentially stimulated in the ovarian tumors of obese 
mice treated with metformin as compared to lean mice, 
suggesting a switch in substrate from fatty acids to 
glucose. The lack of glycolysis in the more aggressive 
tumors in obesity was surprising, since the Warburg effect 
is typically associated with tumorigenesis [83]. However, 
recent reports suggest a more oxidative phenotype may 
prevail in more aggressive cancer models [84]. Indeed, 
as opposed to glucose, the more rapidly growing obese-
OCs appeared to incompletely beta-oxidize fatty acids and 
switch to omega-fatty acid oxidation for ATP production 
and fueling growth as opposed to glucose, as evidenced 
by decreases in n3 and n6 fatty acids and corresponding 
increases in several acyl-carnitines and dicarboxylic 
acids. In addition, succinate levels rose and fumarate and 
malate levels fell in the ovarian tumors from obese versus 
Figure 6: Schematic of metabolic changes in obese and lean endometrial tumors and impact of metformin treatment. 
Metabolic pathways were dysfunctional in obese- versus lean-OCs in KpB mice, reflected by the inability to metabolize 
glucose, heightened omega-fatty acid oxidation for energy production and indications of impaired SDH/complex II. In the 
presence of metformin, complex I was inhibited in the OCs from both lean and obese KpB mice. However, when metformin 
inhibited complex 1 in the complex II impaired ovarian tumors in obese mice, this led to a profound switch in energy 
production from fatty acid oxidation to glycolysis. Lysolipids were also significantly increased in metformin-treated obese-
OCs, leading to further disruption of mitochondrial function.
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Table 2: Comparison of metabolic changes with metformin treatment in the ovarian tumors from obese and lean 
KpB mice
Sub-Pathway Biochemical Name Lean-Met/Lean-Ctrl* Obese-Met/Obese-Ctrl*















Glutamine α-ketoglutarate 1.23 1.53
Oxidation Glucosamine-6-phosphate 0.65 1.8
N-acetylglucosamine-6-phosphate 0.56 2.13
n3 and n6 Eicosapentaenoate 0.54 1.12




















*dark green and red = p<0.05, light green and pink = p<0.1.
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lean mice, indicating impaired succinate dehydrogenase 
(complex II) activity. Mitochondrial dysfunction has 
been reported in tumors cells [85], including that of 
complex II in OC [86]. Lastly, lysolipids were markedly 
decreased in the obese- versus lean-OCs, suggesting that 
lysolipids were being re-acylated as a means to regenerate 
phospholipids for membranes biosynthesis and ultimately 
tumor growth. In summary, our findings suggest that 
obesity promotes alterations in tumor metabolomics that 
is associated with aggressive tumor behavior in the KpB 
OC mouse model.
Upon treatment with metformin, glucose levels 
fell and glycolysis was increased in the ovarian tumors 
of obese mice as compared to lean mice. Metformin is 
known to decrease mitochondrial respiration efficiency 
by inhibiting mitochondrial complex I, thus shifting the 
ATP production burden to anaerobic glycolysis [36, 46, 
57]. In addition, succinate was depleted whereas fumarate 
and malate accumulated in metformin-treated tumors – 
but only in obese mice – a result consistent with restricted 
conversion of malate to oxaloacetate (complex I activity). 
These metabolic changes may underlie why obese-OCs 
have heightened susceptibility to metformin, i.e., obese-
OCs have impaired mitochondrial complex II function that 
- when combined with metformin’s inhibition of complex I 
- leads to profound impairment of mitochondrial oxidative 
phosphorylation. Thus, the obese-OCs may become solely 
dependent on glycolysis for ATP production. Further 
supportive evidence is the dramatic rise in n3 and n6 fatty 
acids with metformin treatment in obese-OCs, indicating 
an inability to oxidize fatty acids when mitochondrial 
complex I and II are inhibited. In obese ovarian tumors, 
lysolipids were also increased with metformin treatment, 
suggesting that phospholipids were being degraded 
perhaps through stimulation of phospholipase A2 
(PLA2) by metformin [87]. Lysolipids have detergent-
like properties that permeabilize membranes [88], and 
thus may further disrupt mitochondrial function in the 
obese-OCs. Glutamate can also be oxidized to generate 
TCA cycle intermediates; this process was induced in the 
metformin-treated obese-OCs, possibly as a mechanism to 
overcome metformin’s inhibitory effects on mitochondrial 
metabolism.
These findings support our hypothesis that 
metformin may have differential direct metabolic effects 
to alter the established metabolic phenotype of ovarian 
tumors in obese versus lean mice, leading to improved 
efficacy in treating tumors which develop in an obese host 
environment. Obese-OCs appear more reliant on fatty acid 
oxidation as opposed to glycolysis for ATP production, 
with coincident impaired mitochondrial complex II 
function. In contrast, the opposite was true for lean-OCs. 
Given that the effects of metformin to inhibit the mTOR 
pathway were similar between ovarian tumors from 
obese and lean mice, we postulate that metformin’s direct 
metabolic effects on inhibition of mitochondrial complex 
I drive the increased response in complex II-impaired 
tumors from obese mice (Figure 6). Clinical trials are 
already underway for metformin in OC patients [89], 
and our findings underscore the importance of evaluating 
the metabolic milieu of a patient and their corresponding 
tumor as potential biomarkers of metformin response in 
cancer therapeutic trials.
MATERIALS AND METHODS
Cell culture and reagents
Four OC cell lines, SKOV3, IGROV1, CAOV3 
and OVCAR3, were used for these experiments. SKOV3 
cells were grown in DMEM/F12 supplemented with 10% 
fetal bovine serum (FBS), 100 units/ml penicillin and 100 
μg/ml streptomycin under 5% CO2. IGROV1, CAOV3 
and OVCAR3 cells were maintained in RPMI 1640 
containing 10% FBS, 100 units/ml penicillin and 100 ug/
ml streptomycin. Metformin, MTT dye, RNase A and anti-
α-tubulin antibody were purchased from Sigma (St. Louis, 
MO). The anti-phosphorylated-AMPK, anti-pan-AMPK, 
anti-phosphorylated-S6 and anti-pan-S6 antibodies as 
well as the caspase-3 ELISA kit were purchased from 
Cell Signaling (Beverly, MA). The Annexin V FITC Kit 
was purchased from BioVison (Mountain View, CA). 
The ChemoTx® Invasion Kit was from NeuroProbe 
(Gaithersburg, MD). Enhanced chemiluminescence 
Western blotting detection reagents were purchased from 
Amersham (Arlington Heights, IL). All other chemicals 
were purchased from Sigma.
Cell proliferation assay
The SKOV3, IGROV1, CAOV3 and OVCAR3 cells 
were plated and grown in 96-well plates at a concentration 
of 4000 to 6000 cells/well for 24 hours (h). Cells were then 
treated with varying doses of metformin for 72 h. Viable 
cell densities were determined by metabolic conversion of 
the dye MTT. MTT (5 mg/ml) was added to the 96-well 
plates at 10 μl/well, and the plates were then incubated 
for an additional 1-2 h. The MTT reaction was terminated 
by the addition of 100 ul DMSO. The MTT assay results 
were read by measuring absorption at 595 nm. The effect 
of metformin was calculated as a percentage of control 
cell growth obtained from PBS (0.1%) treated cells 
grown in the same 96-well plates. Each experiment was 
performed in triplicate and repeated three times to assess 
for consistency of results.
Mitochondrial complex I activity
Mitochondrial complex I activity was 
measured using the Complex I Activity K Assay kit 
from MitoSciences (Eugene, OR), according to the 
manufacturer’s protocol. Briefly, protein was extracted 
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from six well culture plates treated with metformin or 
vehicle by adding the provided detergent solution to each 
well. 50 ug of protein was used to determine the activity of 
complex I. After loading the proteins onto 96 well plates 
coated with an anti-complex I monoclonal antibody, the 
plates were incubated for 3 h at room temperature. Optical 
Density (OD450 nm) was measured using a Tecan plate 
reader in kinetic mode at room temperature for 30 minutes 
(min).
Flow cytometry
The OC cell lines were plated at 2.5-3.5 x 105 cells/
well in 6-well plates in their corresponding media for 24 
h. Subsequently, the cells were treated with metformin 
at varying concentrations for 36 h. Cells were collected, 
washed twice with PBS, fixed in a 90% methanol solution 
and then stored at -20°C until flow cytometric analysis 
was performed. On the day of analysis, cells were washed 
and centrifuged twice using cold PBS, suspended in 100 μl 
PBS and 10 μl of RNase A solution (250 ug/ml), followed 
by incubation for 30 min at 37°C. After incubation, 110 
μl of PI (100 ug/ml) stain was added to each tube and 
incubated at 4°C for at least 30 min prior to analysis. Flow 
cytometric analysis was performed on a CyAn machine 
(Beckman Coulter, Miami, FL). ModFit (Verity Software 
House, Topsham, ME) was utilized for the analysis to 
control for dead cells and debris. All experiments were 
performed in triplicate and repeated twice to assess for 
consistency of response.
Apoptosis assay for caspase 3
The four OC cell lines were cultured in 6-well 
plates at 2-4 x 105 cells/well for 24 h and then treated with 
metformin at various doses in 0.5% stripped serum for an 
additional 24 h. ELISA analysis with a Caspase-3 kit was 
performed according to the manufacturer instructions. 
Briefly, the cells were lysed, and protein concentrations 
measured to confirm equal loading onto an ELISA plate. 
Reagents were added as described by the manufacturer, 
and the ELISA plate was read by measuring absorption at 
450 nm. All experiments were performed in triplicate and 
repeated twice to assess for consistency of response.
Annexin V assay
Annexin V was assessed using the Annexin V-FITC 
Apoptosis Detection Kit. Briefly, the OC cell lines were 
plated at 3 x 105 cells/well in 6-well plates for 24 h, and 
then treated with metfromin at the indicated concentrations 
for 24 h. Cells were collected, washed with PBS and 
resuspended in the binding buffer. 5 μl of annexin V-FITC 
and 5 μl of propidum iodide (PI, 50 μg/ml) were added in 
the binding buffer for 5 min in the dark. The samples were 
immediately measured by BD FacsCalibur flow cytometer 
(BD Biosciences, USA). The results were analyzed by 
Cellquest software. Apoptotic cells were expressed as a 
percentage of the total number of stained cells counted.
Real-time RT-PCR for hTERT
Total RNA was extracted using the RNAqueos kit 
(Ambion, Austin, TX) and further purified by the DNA-
free kit (Ambion). The reverse transcription and PCR 
reactions were performed using the TaqMan Gold one-step 
RT-PCR kit in the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). Reverse 
transcription was carried out at 48°C for 30 min. The 
PCR conditions consisted of a 10 minute step at 95°C, 
40 cycles at 95°C for 15 seconds each and 1 minute at 
65°C. A housekeeping control gene, acidic ribosomal 
phosphoprotein P0 (RPLP0, also known as 36B4), was 
used as an internal control to correct for differences 
in the amount of RNA in each sample. Primers and 
fluorogenic probes for hTERT and RPLP0 have been 
described previously [90]. The standard curve for hTERT 
was generated by using dilutions of a known amount of 
cRNA synthesized by in vitro transcription of a cloned 
fragment. The normalized level of hTERT in each sample 
was estimated by a ratio of the hTERT level to the RPLP0 
level, as described previously [90]. Each experiment was 
performed in triplicate and repeated twice to assess for 
consistency of results.
Western immunoblotting
The SKOV3, IGROV1, CAOV3 and OVCAR3 
cells were plated at 2-4 x 105 cells/well in 6-well plates 
in their corresponding media and then treated for 18 h 
with metformin in 0.5% stripped serum. Cell lysates 
were prepared in RIPA buffer (1% NP40, 0.5 sodium 
deoxycholate and 0.1% SDS) plus PhosStop. Equal 
amounts of protein were separated by gel electrophoresis 
and transferred onto a nitrocellulose membrane. The 
membrane was blocked with 5% nonfat dry milk and 
then incubated with a 1:1000 dilution of primary antibody 
overnight at 4°C. The membrane was then washed and 
incubated with a secondary peroxidase-conjugated 
antibody for 1 h after washing. Antibody binding was 
detected using an enhanced chemiluminescence detection 
buffer and the Alpha Innotech imaging system (San 
Leandro, CA). After developing, the membrane was 
stripped and re-probed using antibodies against pan-S6, 
pan-AMPK and α-tubulin. Each experiment was repeated 
three times to assess for consistency of results.
Measurement of VEGF levels
To measure the vascular endothelial growth factor 
(VEGF) concentration in the serum of mice after exposure 
to metformin, 10 μl of serum was analyzed using a VEGF 
ELISA kit (R&D Systems, Minneapolis, MN), according 
to the manufacturer’s instructions. The optical density at 
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570 nm of each well was measured using a Tecan reader 
(Morrisville, NC).
Adhesion assay
Each well in a 96-well plate was coated with 100 μl 
laminin-1 and incubated at 37°C for 1 h. 200 μl blocking 
buffer was then added to each well for 45-60 min at 37°C. 
The wells were then washed with PBS and the plate was 
allowed to chill on ice. To each well, 2.5 x 103 cells were 
added with PBS and varying concentrations of metformin 
directly. The plate and cell/treatment suspension was then 
allowed to incubate at 37°C for 2 h. The medium was 
then aspirated, and the cells were fixed by directly adding 
100 μl of 5% glutaraldehyde and incubating for 30 min at 
room temperature. Adhered cells were then washed with 
PBS and stained with 100 μl of 0.1% crystal violet for 30 
min. The cells were then washed repeatedly with water, 
and 100 μl of 10% acetic acid was added to each well to 
solubilize the dye. After 5 min of shaking, the absorbance 
was measured at 570 nm using a FLUOstar OMEGA plate 
reader from BMG Labtech (Cary, NC).
Invasion assay
Invasion was assessed with the ChemoTx® invasion 
kit (Gaithersburg, MD). Briefly, cells were starved in 
serum-free medium for 24 h. Cells were then collected, 
washed and resuspended in Gey's Balanced Salt Solution 
+ 1% BSA with varying concentrations of metformin. To 
each well in a 96-well plate, 299 μl of media was added, 
along with varying concentrations of metformin. The 
framed filter membrane was carefully fitted to the top 
of the plate. The plate was allowed to incubate at 37°C 
for 4 h to allow for invasion into the lower compartment. 
These cells were then stained with 3 μl of MTT (5 mg/
mL in RPMI-1640) and allowed to incubate at 37°C for 1 
h. This liquid was then aspirated, the wells were washed 
with PBS, and the MTT dye was solubilized using 20 μl 
of DMSO. The absorbance was then measured at 595 
nm using a FLUOstar OMEGA plate reader from BMG 
Labtech (Cary, NC).
Dietary exposures and metformin treatment in 
the KpB mouse model
For our in vivo studies, we used the K18-gT121
+/-; 
p53fl/fl; Brca1fl/fl (KpB) mouse genetically engineered 
mouse model of serous epithelial OC (generously 
supplied by Terry Van Dyke, PhD, NIH) in which there 
is somatic deletion of Brca1 and p53 and inactivation of 
the retinoblastoma proteins via injection of an adenoviral 
vector expression Cre [91]. All experimental animals were 
maintained in accordance with the Institutional Animal 
Care and Use Committee (IACUC) and the NIH guide for 
the Care and Use of Laboratory Animals. OC generation 
in obese and lean KpB mice was conducted as previously 
described [35]. Three week-old female KpB mice were 
randomly divided into four treatment groups (n=10 per 
group). To mimic diet-induced obesity (DIO), half of the 
mice were subjected to a high fat diet (HFD), in which 
60% of calories were derived from fat, while the other 
half were subjected to a low fat diet (LFD), in which 
only 10% of calories were derived from fat (Research 
Diets, New Brunswick, USA). The HFD and LFD were 
started at 3 weeks of age. At 6 weeks of age, the mice 
were anesthetized with ketamine, and the right ovary was 
exposed. AdCre was delivered into the right ovary using an 
injection of 5 μl of AdCre virus into the ovarian bursa with 
a Hamilton syringe and a 30-gauge beveled needle under 
the control of a dissection microscope. The recombinant 
adenovirus Ad5-CMV-Cre (AdCre) was purchased from 
the University of Iowa Transfer Vector Core at a titre of 
1011-1012 infectious particles/ml.
Mice were maintained on either the LFD or HFD and 
were monitored weekly by palpation for the appearance 
of tumors. Once a 0.1 cm ovarian tumor was palpated, 
HFD-fed and LFD-fed mice initiated treatment with either 
metformin (200 mg/kg, oral gavage) or vehicle (PBS), and 
treatment continued for 4 weeks. Tumor size was checked 
twice a week using palpation until tumors had grown to 
a size amenable to caliper measurement. Tumor volume 
was calculated using the following equation: volume 
(mm3) = (a x b2)/2, where a is the largest diameter and b 
is the smallest diameter. Animals were weighed weekly 
throughout the study. At sacrifice, mice and tumors were 
weighed and blood samples were taken. Half of the tumor 
was snap-frozen and stored at _80°C, and the other half 
was fixed in 10% neutral-buffered formalin and paraffin 
embedded. Pathologic evaluation of histologic findings 
was carried out by a board certified pathologist according 
to existing human epithelial OC classifications.
Immunohistochemistry
Five micrometer paraffin sections, prepared from 
the KpB mice, were used for immunohistochemical (IHC) 
analysis. Staining procedures were performed at the IHC 
Animal Core Facility at the University of North Carolina. 
The following primary antibodies were used: Ki-67 (Cell 
Signaling, 1:800), MMP-9 (Santa Cruz, 1:500), cleaved 
caspase-3 (Cell Signaling, 1:100), phosophorylated-
AMPK and phosphorylated S-6 protein (Cell Signaling, 
1:1000). Further processing was carried out using 
ABC-Staining Kits (Vector Labs, Burlingame, CA) and 
hematoxylin. IHC slides were scanned, analyzed, and 
scored by Aperio and ImageScope software (Vista, CA).
Metabolomic profiling
Metabolomic profiling was performed on ovarian 
tumors obtained from obese and lean KpB mice treated 
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with either vehicle or metformin. Samples were analyzed 
by Metabolon (Research Triangle Park, NC) according 
to their standard protocols 7 [92–95] and our previous 
work [96]. Briefly, unbiased global metabolomic profiling 
was achieved using methanol extracts of tumor tissues 
normalized to tissue weight. Analysis of extracts consisted 
of either ultrahigh performance liquid chromatography 
(Waters Corporation, Milford, MA) coupled with tandem 
mass spectrometry (UHPLC/MS/MS; Thermo-Finnigan, 
San Jose CA) in positive and negative ionization modes, or 
via gas chromatography/MS analysis (Thermo-Finnigan). 
Metabolites in tumor tissues were positively identified 
by matching chromatographic retention time, mass and 
MS/MS fragmentation patterns to a reference library of 
over 2500 purified, authenticated biochemicals. Data are 
presented as relative measures of “scaled intensity” and 
median scaling to 1. Missing values were imputed with 
the minimum.
Statistical analysis
Data are presented as mean ± S.E.M. Statistical 
analysis of the differences between groups was 
determined using the two-sided unpaired Student’s t-test 
using GraphPad software (La Jolla, CA), and a value 
of p<0.05 was considered statistically significant. The 
non-parametric ANOVA was used to test if there were 
differences in metformin’s effects in obese versus lean 
KpB mice.
For the metabolomic profiling, two types of 
statistical analyses were performed: (1) significance tests 
and (2) classification analysis. For pair-wise comparisons, 
Welch’s t-tests and/or Wilcoxon’s rank sum tests were 
performed. Where appropriate, repeated measures analysis 
of variance (ANOVA) was used. For classification 
analysis, random forest analyses were performed. Random 
forest is a supervised classification technique based on 
an ensemble of decision trees [97]. For a given decision 
tree, a random subset of the data with identifying true 
class information is selected to build the tree (“bootstrap 
sample” or “training set”), and then the remaining data, the 
“out-of-bag” (OOB) variables, are passed down the tree to 
obtain a class prediction for each sample. This process is 
repeated thousands of times to produce the forest. The final 
classification of each sample is determined by computing 
the class prediction frequency (“votes”) for the OOB 
variables over the whole forest. Statistical analyses were 
performed with the program “R” (http://cran.r-project.org/).
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